{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:21:09Z","timestamp":1758050469702,"version":"3.44.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"am","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bulcan.2021.12.003","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T15:51:56Z","timestamp":1640965916000},"page":"8-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["L\u2019ann\u00e9e 2021\u00a0dans tous ses \u00e9tats\u00a0: une synth\u00e8se dig\u00e9r\u00e9e"],"prefix":"10.1016","volume":"109","author":[{"given":"Jacques-Olivier","family":"Bay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Bouleuc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Firmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Magne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Orbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Penel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"L\u2019Allemain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Sabatier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.bulcan.2021.12.003_bib0005","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.bulcan.2021.12.003_bib0010","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"10265","key":"10.1016\/j.bulcan.2021.12.003_bib0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3\u00a0clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"suppl_5","key":"10.1016\/j.bulcan.2021.12.003_bib0020","first-page":"S1283","article-title":"LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03\u00a0study","volume":"32","author":"Cort\u00e9s","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0025","doi-asserted-by":"crossref","unstructured":"Makker V, Colombo N, Herr\u00e1ez AC, et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer. Gynecol Oncol 2021;162:S4. [ISSN: 0090-8258].","DOI":"10.1016\/S0090-8258(21)00657-0"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0030","doi-asserted-by":"crossref","unstructured":"Tewari KS, Monk BJ, Vergote I, et al. VP4-2021: EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent\/metastatic (R\/M) cervical carcinoma. Ann Oncol 2021;32(7):940-941. [ISSN: 0923-7534].","DOI":"10.1016\/j.annonc.2021.04.009"},{"issue":"suppl. 4","key":"10.1016\/j.bulcan.2021.12.003_bib0035","doi-asserted-by":"crossref","first-page":"S1164","DOI":"10.1016\/j.annonc.2020.08.2264","article-title":"Single-agent anti-PD-1\u00a0balstilimab or in combination with anti-CTLA-4\u00a0zalifrelimab for recurrent\/metastatic (R\/M) cervical cancer (CC): preliminary results of two independent phase II trials","volume":"31","author":"O\u2019Malley","year":"2020","journal-title":"Ann Oncol"},{"issue":"10308","key":"10.1016\/j.bulcan.2021.12.003_bib0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3\u00a0trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"13\u00a0Supplement","key":"10.1016\/j.bulcan.2021.12.003_bib0045","article-title":"Abstract CT003: nivolumab + platinum-doublet chemotherapy vs. chemotherapy as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer in the phase 3\u00a0CheckMate 816\u00a0trial","volume":"81","author":"Forde","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0050","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","author":"Li","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3\u00a0trial","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2\u00a0trial","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2021.12.003_bib0070","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"7867","key":"10.1016\/j.bulcan.2021.12.003_bib0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"Supplement 5","key":"10.1016\/j.bulcan.2021.12.003_bib0080","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.048","article-title":"652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): results of the GETUG\/AFU VESPER V05\u00a0phase III trial","volume":"32","author":"Pfister","year":"2021","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2021.12.003_bib0085","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.bulcan.2021.12.003_bib0090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2021.12.003_bib0095","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bulcan.2021.12.003_bib0100","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"Supplement 5","key":"10.1016\/j.bulcan.2021.12.003_bib0105","doi-asserted-by":"crossref","first-page":"S1300","DOI":"10.1016\/j.annonc.2021.08.2101","article-title":"LBA25\u00a0Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"32","author":"Armstrong","year":"2021","journal-title":"Ann Oncol"},{"issue":"Supplement 5","key":"10.1016\/j.bulcan.2021.12.003_bib0110","doi-asserted-by":"crossref","first-page":"S1299","DOI":"10.1016\/j.annonc.2021.08.2099","article-title":"LBA5\u00a0A phase III trial with a 2 \u00d7 2\u00a0factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1","volume":"32","author":"Fizazi","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.12.003_bib0115","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617\u00a0for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.12.003_bib0120","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2021.12.003_bib0125","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.003_bib0130","first-page":"vdab075","article-title":"A phase Ib\/IIa trial of 9\u00a0repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","volume":"3","author":"Halatsch","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0135","series-title":"ESTRO meeting","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial. Presentation Number: OC-0333","author":"Laprie","year":"2021"},{"issue":"11","key":"10.1016\/j.bulcan.2021.12.003_bib0140","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1007\/s00330-016-4234-5","article-title":"Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation","volume":"26","author":"Khalifa","year":"2016","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.12.003_bib0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-019-5317-x","article-title":"Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging","volume":"19","author":"Laprie","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2021.12.003_bib0150","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastro-intestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3\u00a0trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","article-title":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastro-intestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial","volume":"145","author":"Jones","year":"2021","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.bulcan.2021.12.003_bib0160","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"journal-title":"LBA59 ESMO meeting","year":"2021","author":"Pautier","key":"10.1016\/j.bulcan.2021.12.003_bib282"},{"issue":"7","key":"10.1016\/j.bulcan.2021.12.003_bib0165","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351\u00a0versus 7 + 3\u00a0cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3\u00a0trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.bulcan.2021.12.003_bib0170","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2021.12.003_bib0175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","article-title":"Blinatumomab + ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"62","author":"Couturier","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0180","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, et al. Daratumumab maintenance vs observation in patients with newly diagnosed multiple myeloma treated with bortezomib, thalidomide, and dexamethasone \u00b1 daratumumab and asct: cassiopeia part 2\u00a0results [Internet]. [Cit\u00e9 2\u00a0nov 2021. Disponible sur\u00a0: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/324588\/philippe.moreau.daratumumab.maintenance.vs.observation.in.patients.with.newly.html]."},{"key":"10.1016\/j.bulcan.2021.12.003_bib0185","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, et al. Overall survival results with daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3\u00a0maia study. [Internet]. [Cit\u00e9 2\u00a0nov 2021. Disponible sur\u00a0: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/330171\/thierry.facon.overall.survival.results.with.daratumumab.lenalidomide.and.html?f=menu=6*browseby=8*sortby=2*ce_id=2035*marker=1284]."},{"issue":"8","key":"10.1016\/j.bulcan.2021.12.003_bib0190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.bulcan.2021.12.003_bib0195","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2\u00a0open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0200","unstructured":"Al-Sawaf O, Zhang C, Robrecht S, Tandon M, Panchal A, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized cll14\u00a0study. [Internet]. [Cit\u00e9 2\u00a0nov 2021. Disponible sur\u00a0: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/324554\/othman.al-sawaf.venetoclax-obinutuzumab.for.previously.untreated.chronic.html?f=listing%3D0\u00a0%2Abrowseby%3D8\u00a0%2Asortby%3D1\u00a0%2Asearch%3Ds146]."},{"issue":"34","key":"10.1016\/j.bulcan.2021.12.003_bib0205","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0210","unstructured":"Kater A, Owen C, Moreno C, Follows G, Munir T, et al. Fixed-duration ibrutinib and venetoclax (i + v) versus chlorambucil plus obinutuzumab (clb + o) for first-line (1l) chronic lymphocytic leukemia (cll): primary analysis of the phase 3\u00a0glow study. [Internet]. [Cit\u00e9 2\u00a0nov 2021. Disponible sur\u00a0: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/330172\/arnon.kater.fixed-duration.ibrutinib.and.venetoclax.28i2Bv29.versus.chlorambucil.html]."},{"issue":"15_suppl.","key":"10.1016\/j.bulcan.2021.12.003_bib0215","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2021.39.15_suppl.7515","volume":"39","author":"Jacobson","year":"2021","journal-title":"JCO"},{"issue":"10299","key":"10.1016\/j.bulcan.2021.12.003_bib0220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19\u00a0for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2\u00a0results of the single-arm, open-label, multicentre ZUMA-3\u00a0study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0225","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19\u00a0CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"journal-title":"J Clin Oncol","year":"2021","author":"Defachelles","key":"10.1016\/j.bulcan.2021.12.003_bib0230"},{"issue":"8","key":"10.1016\/j.bulcan.2021.12.003_bib0235","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2352-4642(21)00159-0","article-title":"Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005\u00a0study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)","volume":"5","author":"Ferrari","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"Suppl. 4","key":"10.1016\/j.bulcan.2021.12.003_bib0240","doi-asserted-by":"crossref","first-page":"e29072","DOI":"10.1002\/pbc.29072","article-title":"The European Paediatric Rare Tumours Network\u00a0\u2013\u00a0European Registry (PARTNER) project for very rare tumors in children","volume":"68","author":"Orbach","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.003_bib0245","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S2352-4642(20)30275-3","article-title":"Predisposition to cancer in children and adolescents","volume":"5","author":"Kratz","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"23","key":"10.1016\/j.bulcan.2021.12.003_bib0250","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.20.03144","article-title":"Randomized trial of two induction therapy regimens for high-risk neuroblastoma: HR-NBL1.5\u00a0International Society of Pediatric Oncology European Neuroblastoma Group Study","volume":"39","author":"Garaventa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00086","article-title":"Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)","author":"Bellini","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2021.12.003_bib0260","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/cancers13092075","article-title":"Treatment and outcome analysis of 639\u00a0relapsed non-Hodgkin lymphomas in children and adolescents and resulting treatment recommendations","volume":"13","author":"Burkhardt","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0265","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs. routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bulcan.2021.12.003_bib0270","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2021.12.003_bib0275","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2021.12.003_bib0280","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1200\/JCO.20.02015","article-title":"Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy","volume":"39","author":"Absolom","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121005786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121005786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:49Z","timestamp":1757792149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121005786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0007455121005786"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.12.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019ann\u00e9e 2021\u00a0dans tous ses \u00e9tats\u00a0: une synth\u00e8se dig\u00e9r\u00e9e","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}